Pediatric Psoriasis

Pediatric psoriasis management requires balancing clinical efficacy with the unique challenges of treating children, including needle phobia and complex insurance requirements. While multiple biologics—such as Etanercept, Ustekinumab, and the recently approved Guselkumab—offer robust options for moderate-to-severe cases, clinical practice often hinges on navigating managed care restrictions and patient anxiety. Pediatric dermatologists prioritize minimizing invasive procedures, with many clinicians favoring agents that allow for less frequent dosing. Beyond biologics, managing comorbidities like psoriatic arthropathy and addressing the psychological impact of chronic skin conditions remain critical. Dr. Doug Kress emphasizes that while systemic therapies have revolutionized treatment, the field still lacks a highly effective, safe oral option that avoids the trauma of frequent injections. Future advancements in pediatric dermatology will likely focus on improving patient adherence and expanding therapeutic access for younger populations.